CTRI/2021/05/033568
Not yet recruiting
Phase 4
An international Phase 4 field study to analyse the psychometric properties of the updated module on assessing quality of life of patients with breast cancer (EORTC QLQ-BR23 Update EORTC QLQ BR45). - EORTC BR45
Dr Vesna Bjelic Radisic0 sites0 target enrollmentTBD
Overview
- Phase
- Phase 4
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Dr Vesna Bjelic Radisic
- Status
- Not yet recruiting
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\) Histologically confirmed diagnosis of breast cancer.
- •2\) No previous primary or recurrent tumor.
- •3\) Ability to understand the language of the questionnaire.
- •4\) Mental fitness to complete a questionnaire.
- •5\) Willing to provide written informed consent.
Exclusion Criteria
- •Exclusion criteria are the negation of the inclusion criteria i.e., no histologically confirmed diagnosis of breast cancer, previous primary or recurrent tumor, not mentally fit to complete a questionnaire, not able to understand the language of the questionnaire, younger than 18, and refusal of informed consent.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
An open, phase IV, multicentre, study to assess the long-term persistence of antibodies against hepatitis B and the immune response to a hepatitis B vaccine challenge in healthy children aged 11-12 years, previously vaccinated with GlaxoSmithKline (GSK) Biologicals’ DTPa-HBV-IPV/Hib vaccine (Infanrix hexa™) or GSK Biologicals’ DTPa-IPV/Hib and HBV (Engerix™- B) vaccines at the ages of 3, 5 and 11 months in clinical trial DTPa-HBV-IPV-031 (217744/031). - DTPa-HBV-IPV-126 BST:031Antibody persistence and hepatitis B vaccine challenge at 11-12 years of age (excluding 13th birthday), after primary vaccination with GSK Biologicals’ DTPa-HBV-IPV/Hib vaccine (Infanrix hexa) or GSK Biologicals’ HBV vaccine (Engerix-B) given at the ages of 3, 5 and 11 months.EUCTR2009-016911-39-SKGlaxoSmithKline Biologicals
Active, not recruiting
Phase 1
A phase IV, open, multicentre, multicountry study to evaluate the immune response to a challenge dose of GSK Biologicals’ Twinrix™ vaccine versus monovalent hepatitis A and B vaccines from different manufacturers in healthy and non-healthy adults aged > 41 years, approximately 48 months after primary vaccination in study 100382 (HAB-160). - HAB-168 BST:160EUCTR2008-000526-39-CZGlaxoSmithKline Biologicals333
Active, not recruiting
Not Applicable
A phase IV, open, multicentre, multicountry study to evaluate the immune response to a challenge dose of GSK Biologicals’ Twinrix™ vaccine versus monovalent hepatitis A and B vaccines from different manufacturers in healthy and non-healthy adults aged > 41 years, approximately 48 months after primary vaccination in study 100382 (HAB-160). - HAB-168 BST 160Healthy and non-healthy (including those taking medications) adults older than 41 years who participated in the primary vaccination study HAB-160 approximately 48 months ago.EUCTR2008-000526-39-BEGlaxoSmithKline Biologicals333
Active, not recruiting
Not Applicable
Study to evaluate immunogenicity, reactogenicity and safety of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy Taiwanese infants who received hepatitis B immunoglobulin after birth.EUCTR2011-003731-63-Outside-EU/EEAGlaxoSmithKline Biologicals15
Active, not recruiting
Phase 1
A phase IV, open, multicenter, multicountry study to assess the long-term antibody persistence of a booster dose of GlaxoSmithKline (GSK) Biologicals’ Haemophilus influenzae type b – meningococcal serogroup C conjugate (Hib-MenC) vaccine given at 12-15 months of age to subjects who were primed in primary study 103974 (HIB-MENC-TT-012) and boosted in study 104056 (HIB-MENC-TT-013 BST:012). - Hib-MenC-TT-027, 028, 029EUCTR2006-006460-32-GBGlaxoSmithKline Biologicals478